Women’s Health and Pulmonary Vascular Disease

9 September 2025

Summary

The Women's Health Task Force was relaunched to address the intersection of women's health and pulmonary vascular disease. The webinar includes research presentations on sex differences and sex hormone treatments in pulmonary arterial hypertension (PAH). Studies show that this disease primarily affects women, but men have worse survival. There has been significant research on the role of sex hormones in this disparity including the phase 3 trial of anastrozole that was presented. The Women's Health Task Force aims to improve knowledge, encourage research, and optimize delivery of clinical care to women with pulmonary vascular disease, with future events planned to foster global collaboration on women's health and pulmonary hypertension.
 

Generated with AI, edited by PVRI

Speakers & moderators

Steve Kawut, University of Pennsylvania School of Medicine, USA
Jackie DesJardin, UCSF Health, USA
Jessica Badlam, University of Vermont Medical Center, USA
Meghan Cirulis, Intermountain Health Intermountain Medical Center, USA
Share: